Polymorphisms in XPD751 Gene and Sensitivity to Chemotherapy in Colorectal Carcinoma

Objective To investigate the relationship between the polymorphisms of DNA repair gene XPD751 and the sensitivity to chemotherapy in advanced colorectal cancer. Methods A total of 98 patients diagnosed as an advanced rectal cancer by the pathology were treated with FOLFOX chemotherapy and DNA of peripheral blood-leukocytes was obtained before the treatment，XPD genetype were detected by the PCR-RFLP method. Results （1）The frequencies of XPD751 Lys/Lys，Lys/Gln，Gln/Gln genetypes were 76 cases (77.55%)，17 cases (17.35%)，5 cases (5.10%) respectively.（2）The effective rate of FOLFOX chemotherapy among patients with XPD751 Lys/Lys，Lys/Gln，Gln/Gln genetypes were 50.00%，29.41% and 20%，respectively，which was a significant difference（χ2=4.04，P<0.05）.Logistic regression model results indicated that the probability of chemotherapy worked on patients with Lys/Lys genetype was 3.80 fold to Lys/Gln(OR=3.80，95%CI：0.985~14.698). Conclusion Single nucleotide polymorphisms of XPD751 correlates with the clinical response to FOLFOX chemotherapy and the XPD751 genetype detected by the PCR-RFLP method may be a predictor of sensitivity to FOLFOX chemotherapy.